Citation
Alhazzani, Waleed, et al. "Surviving Sepsis Campaign: Guidelines On the Management of Critically Ill Adults With Coronavirus Disease 2019 (COVID-19)." Intensive Care Medicine, vol. 46, no. 5, 2020, pp. 854-887.
Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-887.
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., Du, B., Aboodi, M., Wunsch, H., Cecconi, M., Koh, Y., Chertow, D. S., Maitland, K., Alshamsi, F., Belley-Cote, E., ... Rhodes, A. (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 46(5), 854-887. https://doi.org/10.1007/s00134-020-06022-5
Alhazzani W, et al. Surviving Sepsis Campaign: Guidelines On the Management of Critically Ill Adults With Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;46(5):854-887. PubMed PMID: 32222812.
TY - JOUR
T1 - Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19).
AU - Alhazzani,Waleed,
AU - Møller,Morten Hylander,
AU - Arabi,Yaseen M,
AU - Loeb,Mark,
AU - Gong,Michelle Ng,
AU - Fan,Eddy,
AU - Oczkowski,Simon,
AU - Levy,Mitchell M,
AU - Derde,Lennie,
AU - Dzierba,Amy,
AU - Du,Bin,
AU - Aboodi,Michael,
AU - Wunsch,Hannah,
AU - Cecconi,Maurizio,
AU - Koh,Younsuck,
AU - Chertow,Daniel S,
AU - Maitland,Kathryn,
AU - Alshamsi,Fayez,
AU - Belley-Cote,Emilie,
AU - Greco,Massimiliano,
AU - Laundy,Matthew,
AU - Morgan,Jill S,
AU - Kesecioglu,Jozef,
AU - McGeer,Allison,
AU - Mermel,Leonard,
AU - Mammen,Manoj J,
AU - Alexander,Paul E,
AU - Arrington,Amy,
AU - Centofanti,John E,
AU - Citerio,Giuseppe,
AU - Baw,Bandar,
AU - Memish,Ziad A,
AU - Hammond,Naomi,
AU - Hayden,Frederick G,
AU - Evans,Laura,
AU - Rhodes,Andrew,
Y1 - 2020/03/28/
PY - 2020/03/15/received
PY - 2020/03/20/accepted
PY - 2020/3/31/pubmed
PY - 2020/5/15/medline
PY - 2020/3/31/entrez
KW - COVID-19
KW - Clinical practice guidelines
KW - Coronavirus
KW - Critical illness
KW - SARS CoV-2
SP - 854
EP - 887
JF - Intensive care medicine
JO - Intensive Care Med
VL - 46
IS - 5
N2 - BACKGROUND: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting thousands of people around the world. Urgent guidance for clinicians caring for the sickest of these patients is needed. METHODS: We formed a panel of 36 experts from 12 countries. All panel members completed the World Health Organization conflict of interest disclosure form. The panel proposed 53 questions that are relevant to the management of COVID-19 in the ICU. We searched the literature for direct and indirect evidence on the management of COVID-19 in critically ill patients in the ICU. We identified relevant and recent systematic reviews on most questions relating to supportive care. We assessed the certainty in the evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach, then generated recommendations based on the balance between benefit and harm, resource and cost implications, equity, and feasibility. Recommendations were either strong or weak, or in the form of best practice recommendations. RESULTS: The Surviving Sepsis Campaign COVID-19 panel issued 54 statements, of which 4 are best practice statements, 9 are strong recommendations, and 35 are weak recommendations. No recommendation was provided for 6 questions. The topics were: (1) infection control, (2) laboratory diagnosis and specimens, (3) hemodynamic support, (4) ventilatory support, and (5) COVID-19 therapy. CONCLUSION: The Surviving Sepsis Campaign COVID-19 panel issued several recommendations to help support healthcare workers caring for critically ill ICU patients with COVID-19. When available, we will provide new recommendations in further releases of these guidelines.
SN - 1432-1238
UR - https://www.unboundmedicine.com/medline/citation/32222812/full_citation
L2 - https://dx.doi.org/10.1007/s00134-020-06022-5
DB - PRIME
DP - Unbound Medicine
ER -